Payment overview · 2025
General Payments
$4,277.89
204 reported records · 34 companies
Healthcare provider profile · identity verified
Jehad E Saliba, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · KEARNY, NJ · NPI 1164480372
Verified facts
What the public records show
CMS Open Payments records show Jehad E Saliba, MD received $4,277.89 in general payments during 2025 across 204 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 49 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Acthar, Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 527 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 351 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 527 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
Mallinckrodt Hospital Products Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ACTHAR as an associated drug or biological on 35914 records involving 11592 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Acthar by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 406 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Soliqua 100-33 by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ztlido by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,121.63 | 26.2% | 46 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $603.47 | 14.1% | 25 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $529.33 | 12.4% | 30 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $302.30 | 7.1% | 12 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $270.08 | 6.3% | 10 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $145.93 | 3.4% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $144.62 | 3.4% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $120.87 | 2.8% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $99.73 | 2.3% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $85.88 | 2.0% | 5 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $79.26 | 1.9% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.20 | 1.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $65.96 | 1.5% | 4 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.58 | 1.5% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $55.49 | 1.3% | 3 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $53.91 | 1.3% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $48.38 | 1.1% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $47.67 | 1.1% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $40.72 | 0.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $36.69 | 0.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $35.92 | 0.8% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $35.74 | 0.8% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $32.74 | 0.8% | 2 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $24.02 | 0.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.22 | 0.5% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $18.52 | 0.4% | 1 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $17.96 | 0.4% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.71 | 0.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.59 | 0.4% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $16.43 | 0.4% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $15.80 | 0.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.87 | 0.3% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.74 | 0.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.93 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,277.89 | 204 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $636.73 | 25 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $500.42 | 20 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $410.62 | 24 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $285.88 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $219.04 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $170.76 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $166.61 | 10 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $163.91 | 9 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $145.93 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $118.71 | 6 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $114.77 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $109.15 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $99.73 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $85.88 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $84.05 | 4 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $79.26 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $73.48 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.49 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.49 | 4 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $67.20 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $62.58 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $55.49 | 3 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $53.91 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $48.38 | 3 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $47.67 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $40.72 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $36.69 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $35.74 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $32.74 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.49 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.49 | 2 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Monarch Airway Clearance System Normalized: hillrom monarch airway clearance system |
Device | Baxter Healthcare | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ACTHAR acthar |
2025 | Acthar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 406 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 212 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 527 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 138 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 301 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 39 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 54 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 351 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
69 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
212 | 61 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
527 | 123 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
351 | 82 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
527 | 123 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
138 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | 19 |
| Mallinckrodt Hospital Products Inc. Exact reporting entity; no affiliate inference |
2025 | ACTHAR open payments reported associated product |
CMS Open Payments — General Payments 35914 supporting records · 11592 recipient NPIs · example record 1211945432 |
Acthar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
301 | 59 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
54 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
406 | 59 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
39 | 39 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1491 | 407 |
| Prednisone | Prednisone | 974 | 536 |
| Metformin Hcl | Metformin Hcl | 869 | 278 |
| Pantoprazole Sodium | Pantoprazole Sodium | 849 | 272 |
| Levothyroxine Sodium | Levothyroxine Sodium | 679 | 179 |
| Losartan Potassium | Losartan Potassium | 630 | 195 |
| Amlodipine Besylate | Amlodipine Besylate | 626 | 177 |
| Metoprolol Succinate | Metoprolol Succinate | 619 | 185 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 596 | 182 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 577 | 194 |
| Alprazolam | Alprazolam | 551 | 113 |
| Jardiance | Empagliflozin | 527 | 123 |
| Eliquis | Apixaban | 406 | 59 |
| Azithromycin | Azithromycin | 360 | 256 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 351 | 82 |
| Gabapentin | Gabapentin | 350 | 101 |
| Fluticasone Propionate | Fluticasone Propionate | 345 | 130 |
| Zolpidem Tartrate | Zolpidem Tartrate | 319 | 51 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 312 | 121 |
| Furosemide | Furosemide | 311 | 87 |
| Simvastatin | Simvastatin | 306 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 305 | 90 |
| Ozempic | Semaglutide | 301 | 59 |
| Montelukast Sodium | Montelukast Sodium | 289 | 86 |
| Doxycycline Hyclate | Doxycycline Hyclate | 288 | 239 |
| Escitalopram Oxalate | Escitalopram Oxalate | 276 | 78 |
| Lisinopril | Lisinopril | 230 | 60 |
| Breo Ellipta | Fluticasone/Vilanterol | 221 | 54 |
| Ezetimibe | Ezetimibe | 221 | 77 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 217 | 108 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 214 | 64 |
| Farxiga | Dapagliflozin Propanediol | 212 | 61 |
| Omeprazole | Omeprazole | 211 | 71 |
| Clopidogrel | Clopidogrel Bisulfate | 195 | 54 |
| Ibandronate Sodium | Ibandronate Sodium | 181 | 55 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 174 | 51 |
| Promethazine Hcl | Promethazine Hcl | 170 | 122 |
| Januvia | Sitagliptin Phosphate | 167 | 41 |
| Famotidine | Famotidine | 157 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 39 |
| Fenofibrate | Fenofibrate Nanocrystallized | 153 | 54 |
| Allopurinol | Allopurinol | 151 | 46 |
| Meloxicam | Meloxicam | 149 | 50 |
| Xarelto | Rivaroxaban | 144 | 32 |
| Mirtazapine | Mirtazapine | 143 | 24 |
| Mounjaro | Tirzepatide | 138 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 43 |
| Sertraline Hcl | Sertraline Hcl | 135 | 32 |
| Carvedilol | Carvedilol | 134 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 127 | 77 |
| Vascepa | Icosapent Ethyl | 124 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 121 | 93 |
| Memantine Hcl | Memantine Hcl | 116 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 111 | 43 |
| Donepezil Hcl | Donepezil Hcl | 111 | 25 |
| Levofloxacin | Levofloxacin | 111 | 89 |
| Diclofenac Sodium | Diclofenac Sodium | 108 | 29 |
| Celecoxib | Celecoxib | 105 | 42 |
| Lorazepam | Lorazepam | 102 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 101 | 29 |
| Trazodone Hcl | Trazodone Hcl | 100 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 92 | 24 |
| Potassium Chloride | Potassium Chloride | 91 | 27 |
| Buspirone Hcl | Buspirone Hcl | 90 | 27 |
| Mupirocin | Mupirocin | 90 | 54 |
| Alendronate Sodium | Alendronate Sodium | 88 | 19 |
| Glimepiride | Glimepiride | 88 | 28 |
| Meclizine Hcl | Meclizine Hcl | 85 | 56 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 17 |
| Clonazepam | Clonazepam | 81 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 80 | 39 |
| Paroxetine Hcl | Paroxetine Hcl | 75 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 21 |
| Glipizide | Glipizide | 69 | 21 |
| Myrbetriq | Mirabegron | 69 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 18 |
| Midodrine Hcl | Midodrine Hcl | 64 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 63 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 62 | 18 |
| Trulicity | Dulaglutide | 61 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 15 |
| Enalapril Maleate | Enalapril Maleate | 59 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 58 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 58 | 25 |
| Valsartan | Valsartan | 58 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 12 |
| Spironolactone | Spironolactone | 56 | 19 |
| Levetiracetam | Levetiracetam | 55 | suppressed |
| Pregabalin | Pregabalin | 55 | 13 |
| Tradjenta | Linagliptin | 55 | 11 |
| Rybelsus | Semaglutide | 54 | 18 |
| Torsemide | Torsemide | 54 | 17 |
| Lidocaine | Lidocaine | 53 | 20 |
| Ibuprofen | Ibuprofen | 52 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 14 |
| Ramipril | Ramipril | 51 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 12 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 50 | suppressed |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Diazepam | Diazepam | 49 | 14 |
| Lactulose | Lactulose | 49 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 49 | 15 |
| Synthroid | Levothyroxine Sodium | 49 | 14 |
| Clonidine Hcl | Clonidine Hcl | 45 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 45 | 16 |
| Repatha Sureclick | Evolocumab | 45 | suppressed |
| Roflumilast | Roflumilast | 45 | 11 |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Fluconazole | Fluconazole | 44 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 42 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 17 |
| Spiriva Respimat | Tiotropium Bromide | 44 | 13 |
| Atenolol | Atenolol | 42 | 13 |
| Irbesartan | Irbesartan | 42 | suppressed |
| Eszopiclone | Eszopiclone | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 40 | suppressed |
| Temazepam | Temazepam | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 32 |
| Paxlovid | Nirmatrelvir/Ritonavir | 39 | 39 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 30 |
| Diclofenac Potassium | Diclofenac Potassium | 36 | 13 |
| Finasteride | Finasteride | 36 | 13 |
| Hydrocortisone | Hydrocortisone | 36 | 18 |
| Linzess | Linaclotide | 36 | 11 |
| Nystatin | Nystatin | 36 | 22 |
| Sucralfate | Sucralfate | 36 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 35 | 34 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 35 | 12 |
| Fenofibrate | Fenofibrate | 33 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Creon | Lipase/Protease/Amylase | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Metolazone | Metolazone | 30 | suppressed |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 19 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 27 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Dupixent Pen | Dupilumab | 26 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Livalo | Pitavastatin Calcium | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 11 |
| Ammonium Lactate | Ammonium Lactate | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | 14 |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 23 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 22 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 17 |
| Repaglinide | Repaglinide | 22 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 22 | 13 |
| Silver Sulfadiazine | Silver Sulfadiazine | 22 | 11 |
| Amantadine | Amantadine Hcl | 21 | suppressed |
| Fasenra Pen | Benralizumab | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Tadalafil | Tadalafil | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 19 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 17 |
| Gemtesa | Vibegron | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Ztlido | Lidocaine | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 16 |
| Procrit | Epoetin Alfa | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Acthar | Corticotropin | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Budesonide Er | Budesonide | 12 | suppressed |
| Calcipotriene | Calcipotriene | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,277.89 · 204 records | AstraZeneca Pharmaceuticals LP | ACTHAR, Auvelity, BREZTRI, CAPLYTA, CHARTIS CATHETER, Cologuard Collection Kit, DUPIXENT, EDARBI, ELIQUIS, FARXIGA, FASENRA, GEMTESA, GVOKE HYPOPEN, Hillrom - Monarch Airway Clearance System, JARDIANCE, JASCAYD, KEYTRUDA, LOREEV XR, MOUNJARO, NUCALA, NURTEC ODT, OFEV, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PULMONX CHARTIS TABLET CONSOLE, PURIFIED CORTROPHIN GEL, Prospera, QUTENZA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TEZSPIRE, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, UBRELVY, Veozah, Vest Therapy Und, WAKIX, Wegovy, XIFAXAN, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE, ZORYVE, ZTLido | 23 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Acthar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error